Zhou Irene S, Zhu Dagny C
School of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
NVISION Eye Centers, Rowland Heights, CA, USA.
Clin Ophthalmol. 2025 Aug 9;19:2625-2635. doi: 10.2147/OPTH.S533091. eCollection 2025.
To evaluate cataract surgery outcomes following mix-and-match implantation of a trifocal and extended-depth-of-focus (EDOF) intraocular lens (IOL).
Single center, private practice.
Single arm, non-interventional, ambispective study.
Patients who underwent femtosecond-laser assisted cataract surgery with mix-and-match implantation of the Clareon PanOptix trifocal IOL in the non-dominant eye and Clareon Vivity EDOF IOL in the dominant eye from September 2022 to November 2023 were reviewed. Only healthy eyes with postoperative absolute spherical equivalent (SE) ≤ 0.50 diopters (D) and cylinder ≤ 0.75 D were included. At 3 months postoperatively, binocular corrected and uncorrected visual acuity at distance (CDVA and UDVA), intermediate (DCIVA and UIVA), and near (DCNVA and UNVA) along with patient-reported outcomes (QUVID and IOLSAT questionnaires) were assessed.
100 eyes of 50 patients were included. Postoperatively, the mean binocular CDVA and UDVA was -0.08 ± 0.05 logMAR and -0.06 ± 0.05 logMAR, respectively. Overall, 100%, 98%, and 90% of patients achieved binocular UDVA, UIVA, and UNVA of 20/25 or better, respectively. Eighty-four percent of patients reported complete spectacle independence. Few patients were "bothered very much" by haloes, glare, or starbursts (0-4%). No patients reported dissatisfaction with their vision. Overall, 94% and 92% of patients would elect the same IOLs and recommend the same procedure to friends and family, respectively.
Mix-and-match implantation of the Clareon PanOptix and Vivity IOLs yields good patient satisfaction potentially by combining the advantages of each lens resulting in a high degree of satisfaction and low rates of visual disturbances.
评估三焦点与扩展景深(EDOF)人工晶状体(IOL)混合搭配植入后的白内障手术效果。
单中心,私人诊所。
单臂、非干预性、双视角研究。
回顾2022年9月至2023年11月期间接受飞秒激光辅助白内障手术的患者,其非主导眼植入Clareon PanOptix三焦点IOL,主导眼植入Clareon Vivity EDOF IOL。仅纳入术后绝对球镜等效度(SE)≤0.50屈光度(D)且柱镜≤0.75 D的健康眼。术后3个月,评估双眼在远距(矫正和未矫正视力,即CDVA和UDVA)、中距(DCIVA和UIVA)和近距(DCNVA和UNVA)的视力,以及患者报告的结果(QUVID和IOLSAT问卷)。
纳入50例患者的100只眼。术后,双眼平均CDVA和UDVA分别为-0.08±0.05 logMAR和-0.06±0.05 logMAR。总体而言,分别有100%、98%和90%的患者双眼UDVA、UIVA和UNVA达到20/25或更好。84%的患者报告完全脱离眼镜。很少有患者受到光晕、眩光或星芒的“严重困扰”(0 - 4%)。没有患者对其视力表示不满。总体而言,分别有94%和92%的患者会选择相同的IOL,并向朋友和家人推荐相同的手术。
Clareon PanOptix和Vivity IOL的混合搭配植入可能通过结合每种晶状体的优点,使患者满意度良好,从而获得高度满意度和低视觉干扰率。